Further analysis of ADAM17's differential expression by rheumatic disease types revealed statistically significant expression in PM/DM and RA with ILD patients, but not in pSS with ILD patients (Figure 1B–D). This evidence concerns the gene ADAM17 and interstitial lung disease.